Results 11 to 20 of about 19,613 (205)

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy [PDF]

Journal of Cardiovascular Development and Disease
The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten.
Benedetto Ferraresi, Antonio Nenna, Mohamad Jawabra, Diletta Corrado, Andrea Faggiano, Stefano Carugo, Carmelo Dominici, Giovanni Casali, Massimo Chello, Mario Lusini   +9 more
doaj   +2 more sources

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]

Cardiologia Hungarica, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the core molecular defect of the disease, by selectively ...
Pálinkás, Eszter Dalma, Sepp, Róbert, Olivotto, Iacopo   +2 more
exaly   +3 more sources

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy [PDF]

The Egyptian Heart Journal
Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Boluwaduro Abasiekem Adeyemi, Bright Nwatamole, Komolafe Babajide Ayodeji, Oshomoh Mark-Anthony Ugiomoh, Temiloluwa Adebayo Odeniyi, Adewunmi Akingbola, Efosa Peace Iyawe, Olabode Olawale Oladejo, Motunrayo Oluwatoyosi Lawal, Nathnael Abera Woldehana, Ifeoluwa Sandra Bakare, Adejumo Temilade Patience, Grace Chinenye Okoro   +14 more
doaj   +2 more sources

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy [PDF]

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) represents the most common inherited cardiac disease and a leading cause of heart failure, arrhythmias, and sudden cardiac death in young individuals.
Farbod Sedaghat-Hamedani, Elham Kayvanpour, Benjamin Meder   +2 more
doaj   +2 more sources

The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review. [PDF]

Heart Fail Rev
Abstract Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular, non-dilated hypertrophy in the absence of another secondary underlying cause. There has been an ongoing increase in the diagnosis of HCM over the past couple of decades, prompting further work in the area of pharmacological and ...
Othman L, Koskina L, Huerta N, Rao SJ.
europepmc   +3 more sources

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis [PDF]

Archives of Medical Science: Atherosclerotic Diseases
Introduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Mohammad Hazique, Sameer Lohana, Sunam Kafle, Jasgit Bhinder, Kunal N. Patel, Jawad Basit, Abdul Rasheed Bahar, Jared Kvapil, M. Chadi Alraies   +8 more
doaj   +2 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +2 more sources

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: advancing care with caution. [PDF]

Ann Med Surg (Lond)
Rehman Z, Ahsaan F, Latif B, Anjum AF, Yokolo H.   +4 more
europepmc   +3 more sources

Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions [PDF]

Diseases
Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Arterial hypertension represents the leading modifiable risk factor for cardiovascular morbidity and mortality globally.
Vasiliki Katsi, Konstantia Papadomarkaki, Konstantinos Manousiadis, Epameinondas Triantafyllou, Christos Fragoulis, Konstantinos Tsioufis   +5 more
doaj   +2 more sources

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies

Frontiers in Physiology, 2022
Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death.
Masataka Kawana, Masataka Kawana, James A. Spudich, Kathleen M. Ruppel   +3 more
doaj   +1 more source